secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034430
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion Q4 2023 revenue drops to $8.2M from $19.2M; operating loss widens to $25.7M
--------------------------------------------------------------------------------

- Q4 2023 revenue $8.2M (down 57% YoY); full year 2023 revenue $53.5M.
- Q4 operating loss $25.7M vs $10.1M in Q4 2022, driven by $7M AR reserves and $3M stock comp.
- Cash and equivalents $38M at Dec 31, 2023; targeting ~$30M cash burn for 2024.
- Reiterates 2024 guidance: revenue $60-65M, 20% procedural volume growth, 77-79% gross margins.
- Completed AUDACITY pivotal trial enrollment for FDA PMA; first UK NHS reimbursed patients treated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000095017024034430/0000950170-24-034430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000095017024034430/alur-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer